Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues

Simply Wall StNov 1 18:15 ET

Report for the third quarter of 2024 of Harbin Pharmaceutical Group Co., Ltd.

SZSIOct 25 12:00 ET · Announcements

Harbin Pharmaceutical Group (600664.SH): net income of 0.508 billion yuan in the first three quarters, a year-on-year increase of 74.97%.

On October 25th, Pharmaron Group (600664.SH) released its third quarter report, with revenue for the first three quarters reaching 12.256 billion yuan, a year-on-year increase of 6.63%. Net income was 0.508 billion yuan, up 74.97% year-on-year, non-GAAP net income was 0.47 billion yuan, up 91.39% year-on-year, and basic earnings per share was 0.20 yuan.

Gelonghui FinanceOct 25 04:21 ET

Harbin Pharmaceutical Group (600664.SH) released its performance for the first three quarters, with a net income of 0.508 billion yuan, a year-on-year increase of 74.97%.

harbin pharmaceutical group (600664.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue...

Zhitong FinanceOct 25 04:12 ET

These 4 Measures Indicate That Harbin Pharmaceutical Group (SHSE:600664) Is Using Debt Safely

Simply Wall StOct 9 01:40 ET

Shareholders in Harbin Pharmaceutical Group (SHSE:600664) Have Lost 26%, as Stock Drops 5.0% This Past Week

Simply Wall StSep 12 19:31 ET